Session 1: An unmet clinical and research need
The Bladder Cancer Prognosis Programme was established in 2005 with CRUK funding, recruiting newly-diagnosed bladder cancer patients from around the West Midlands into a cohort study of five inter-linked projects and incorporating biospecimen collection and a clinical trial, SELENIB (overview attached). These data and biospecimens have fuelled a plethora of translational epidemiological and biological research which have spawned over 30 publications and multiple PhDs. In this session, Rik will provide an overview of the programme and its outputs, highlighting findings of particular importance and the scientific themes that are now being pursued.
Deborah Enting is a Consultant Medical Oncologist at Guy’s and St Thomas’ NHS Foundation Trust and specialises in urological malignancies and has a particular interest in bladder cancer. She completed her undergraduate training at The University of Groningen in The Netherlands before moving to the UK for specialist training in Oncology at Guy’s Hospital. As an academic trainee she completed a PhD with Prof Adrian Hayday at King’s College London in tumour immune surveillance. She is a principle investigator on various bladder cancer clinical trials and has been instrumental in the set up of the King’s Health Partners Bladder Cancer Biobank. Her academic interest focuses on lymphoid stress-surveillance by gamma delta T cell and NK cells in the context of bladder cancer. Deborah will give an overview of progress and ongoing research in the field on bladder cancer immunobiology.
An unmet need from the patients' perspective
Early diagnosis is key to improving survival rates in bladder cancer. GPs are not always aware of the symptoms of bladder cancer, such as blood in the urine and recurrent urinary tract infections. Once a person is correctly diagnosed and starts to discuss treatment, it is essential that their multi-disciplinary treatment team ensures that they understand all the benefits and risks involved. By bringing patient groups, health professionals, and policy-makers together, we can all work towards earlier diagnosis, increased awareness, and better communication, in order to improve the care of Europeans diagnosed with bladder cancer.
Session 1: An unmet clinical and research need
Mr. Rajesh Nair (Raj) is a Consultant Urological Surgeon with a special interest in open, laparoscopic and robotic surgery with a particular focus in uro-oncology and reconstruction (bladder, kidney & prostate cancer).
Raj completed his higher specialist training on the South Thames London Deanery rotation where he was awarded the FRCS (Urol.) and FEBU. He has completed advanced fellowship training in robotics, uro-oncology and reconstruction at St. George’s Hospital, Guy’s Hospital, London & the Royal Melbourne Hospital & Peter MacCallum Cancer Centre in Melbourne, Australia.
Raj has expertise in the investigation & treatment of non-muscle & muscle invasive bladder cancer, open & minimally invasive kidney & prostate cancer surgery.
He is lead for the Upper Tract Urothelial Cancer Programme & is currently involved in the bladder preservation, robotic cystectomy & partial nephrectomy programme at Guy’s Hospital. His current research interests are in the field of upper tract urothelial carcinoma, imaging techniques in bladder cancer diagnostics & improving outcomes following radical cystectomy.
Session 3: Poster presentations
we invite participants from their respective units to submit and present their research. Three high impact abstracts will be selected for an oral presentation and the three best poster presentations will be awarded with an EACR poster prize.
Abstracts need to be submitted as a word document via email to firstname.lastname@example.org by 15 February 2019. Abstracts should be structured (background, methods, results, conclusion) and be no longer than 300 words. All authors should be listed, including their affiliation.
Session 4: EACR-sponsored Plenary speaker
Genomic and Functional Approaches to Identify DNA Repair Biomarkers in MIBC
IDNA repair pathway alterations are common in tumors and can drive genomic instability, tumor evolution, and therapy response. In bladder cancer, somatic alterations in DNA repair genes are associated with improved response to cisplatin-based chemotherapy as well as immune checkpoint blockade. However, the mechanisms through which alterations in specific DNA repair pathways contribute to the tumor mutational landscape, modulate intracellular signaling, and drive treatment response across disease contexts remains poorly understood. We are using a combination of genomic and functional approaches to study the role of DNA repair deficiency as a biomarker and therapeutic target in muscle-invasive bladder cancer.